CN105477171A - 一种用于治疗高脂血症的胶囊及制备方法 - Google Patents
一种用于治疗高脂血症的胶囊及制备方法 Download PDFInfo
- Publication number
- CN105477171A CN105477171A CN201610032104.XA CN201610032104A CN105477171A CN 105477171 A CN105477171 A CN 105477171A CN 201610032104 A CN201610032104 A CN 201610032104A CN 105477171 A CN105477171 A CN 105477171A
- Authority
- CN
- China
- Prior art keywords
- parts
- capsule
- fructus
- hyperlipemia
- herba
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 56
- 201000005577 familial hyperlipidemia Diseases 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 239000002994 raw material Substances 0.000 claims abstract description 14
- 241000218176 Corydalis Species 0.000 claims abstract description 10
- 210000000582 semen Anatomy 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000000284 extract Substances 0.000 claims description 10
- 241000218158 Clematis Species 0.000 claims description 9
- 241000628997 Flos Species 0.000 claims description 9
- 241000325845 Leontopodium leontopodioides Species 0.000 claims description 9
- 241001057584 Myrrha Species 0.000 claims description 9
- 241000212324 Oenanthe <angiosperm> Species 0.000 claims description 9
- 239000012153 distilled water Substances 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 9
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 238000012545 processing Methods 0.000 claims description 6
- 239000009526 Fructus Akebiae Substances 0.000 claims description 5
- 238000002481 ethanol extraction Methods 0.000 claims description 4
- 235000007164 Oryza sativa Nutrition 0.000 claims description 3
- 238000007654 immersion Methods 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 235000009566 rice Nutrition 0.000 claims description 3
- 238000009738 saturating Methods 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000000052 vinegar Substances 0.000 claims description 3
- 235000021419 vinegar Nutrition 0.000 claims description 3
- 241000722953 Akebia Species 0.000 claims 3
- 240000007594 Oryza sativa Species 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 34
- 239000008280 blood Substances 0.000 abstract description 34
- 239000003814 drug Substances 0.000 abstract description 26
- 208000002193 Pain Diseases 0.000 abstract description 20
- 210000002784 stomach Anatomy 0.000 abstract description 16
- 210000004185 liver Anatomy 0.000 abstract description 14
- 230000017531 blood circulation Effects 0.000 abstract description 12
- 208000024891 symptom Diseases 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 11
- 210000000952 spleen Anatomy 0.000 abstract description 10
- 208000002173 dizziness Diseases 0.000 abstract description 9
- 230000036772 blood pressure Effects 0.000 abstract description 8
- 235000013305 food Nutrition 0.000 abstract description 8
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract description 6
- 206010022437 insomnia Diseases 0.000 abstract description 6
- 230000003213 activating effect Effects 0.000 abstract description 3
- 206010008479 Chest Pain Diseases 0.000 abstract description 2
- 238000011161 development Methods 0.000 abstract description 2
- 230000014759 maintenance of location Effects 0.000 abstract description 2
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- 235000007756 Akebia quinata Nutrition 0.000 abstract 1
- 240000008027 Akebia quinata Species 0.000 abstract 1
- 241000512259 Ascophyllum nodosum Species 0.000 abstract 1
- 235000011305 Capsella bursa pastoris Nutrition 0.000 abstract 1
- 240000008867 Capsella bursa-pastoris Species 0.000 abstract 1
- 240000006432 Carica papaya Species 0.000 abstract 1
- 235000009467 Carica papaya Nutrition 0.000 abstract 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract 1
- 244000020518 Carthamus tinctorius Species 0.000 abstract 1
- 240000007311 Commiphora myrrha Species 0.000 abstract 1
- 235000006965 Commiphora myrrha Nutrition 0.000 abstract 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 abstract 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 abstract 1
- 235000009685 Crataegus X maligna Nutrition 0.000 abstract 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 abstract 1
- 235000009486 Crataegus bullatus Nutrition 0.000 abstract 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 abstract 1
- 235000009682 Crataegus limnophila Nutrition 0.000 abstract 1
- 240000000171 Crataegus monogyna Species 0.000 abstract 1
- 235000004423 Crataegus monogyna Nutrition 0.000 abstract 1
- 235000002313 Crataegus paludosa Nutrition 0.000 abstract 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 abstract 1
- 240000008620 Fagopyrum esculentum Species 0.000 abstract 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 abstract 1
- 240000008415 Lactuca sativa Species 0.000 abstract 1
- 235000003228 Lactuca sativa Nutrition 0.000 abstract 1
- 241000226556 Leontopodium alpinum Species 0.000 abstract 1
- 244000211187 Lepidium sativum Species 0.000 abstract 1
- 235000007849 Lepidium sativum Nutrition 0.000 abstract 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 abstract 1
- 235000007265 Myrrhis odorata Nutrition 0.000 abstract 1
- 235000011925 Passiflora alata Nutrition 0.000 abstract 1
- 235000000370 Passiflora edulis Nutrition 0.000 abstract 1
- 235000011922 Passiflora incarnata Nutrition 0.000 abstract 1
- 240000002690 Passiflora mixta Species 0.000 abstract 1
- 235000013750 Passiflora mixta Nutrition 0.000 abstract 1
- 235000013731 Passiflora van volxemii Nutrition 0.000 abstract 1
- 206010037660 Pyrexia Diseases 0.000 abstract 1
- 240000004980 Rheum officinale Species 0.000 abstract 1
- 235000008081 Rheum officinale Nutrition 0.000 abstract 1
- 240000003768 Solanum lycopersicum Species 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 231100000862 numbness Toxicity 0.000 abstract 1
- 238000005728 strengthening Methods 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 description 18
- 210000003414 extremity Anatomy 0.000 description 9
- 210000002435 tendon Anatomy 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000004880 Polyuria Diseases 0.000 description 6
- 210000001015 abdomen Anatomy 0.000 description 6
- 210000000038 chest Anatomy 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- 230000035619 diuresis Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 208000001848 dysentery Diseases 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 206010007247 Carbuncle Diseases 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 5
- 238000012790 confirmation Methods 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 201000006549 dyspepsia Diseases 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 201000007227 lymph node tuberculosis Diseases 0.000 description 5
- 231100000614 poison Toxicity 0.000 description 5
- 239000003440 toxic substance Substances 0.000 description 5
- 230000008736 traumatic injury Effects 0.000 description 5
- 201000000736 Amenorrhea Diseases 0.000 description 4
- 206010001928 Amenorrhoea Diseases 0.000 description 4
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 4
- 206010019909 Hernia Diseases 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 4
- 231100000540 amenorrhea Toxicity 0.000 description 4
- 241000411851 herbal medicine Species 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 206010027175 memory impairment Diseases 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 206010000087 Abdominal pain upper Diseases 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 208000005171 Dysmenorrhea Diseases 0.000 description 3
- 206010013935 Dysmenorrhoea Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010018498 Goitre Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 235000019636 bitter flavor Nutrition 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 208000001780 epistaxis Diseases 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 201000003872 goiter Diseases 0.000 description 3
- 208000006750 hematuria Diseases 0.000 description 3
- 230000023597 hemostasis Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 201000004792 malaria Diseases 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 201000008383 nephritis Diseases 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000003932 urinary bladder Anatomy 0.000 description 3
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 2
- 206010003011 Appendicitis Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 2
- 206010010726 Conjunctival oedema Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010019468 Hemiplegia Diseases 0.000 description 2
- 206010049077 Hernia pain Diseases 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 208000008930 Low Back Pain Diseases 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 206010050031 Muscle strain Diseases 0.000 description 2
- 241000209094 Oryza Species 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 208000037111 Retinal Hemorrhage Diseases 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 2
- 206010053615 Thermal burn Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 206010048214 Xanthoma Diseases 0.000 description 2
- 206010048215 Xanthomatosis Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000000507 anthelmentic effect Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 201000009361 ascariasis Diseases 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 206010013990 dysuria Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 230000000552 rheumatic effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229960002855 simvastatin Drugs 0.000 description 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 2
- 206010040872 skin infection Diseases 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000004371 toothache Diseases 0.000 description 2
- DBTMGCOVALSLOR-DEVYUCJPSA-N (2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000010470 Ageusia Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 240000004528 Catalpa ovata Species 0.000 description 1
- 235000010005 Catalpa ovata Nutrition 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010009168 Chyluria Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 235000017159 Crataegus pinnatifida Nutrition 0.000 description 1
- 241000657480 Crataegus pinnatifida Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 206010060710 Galactostasis Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000037319 Hepatitis infectious Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 239000005717 Laminarin Substances 0.000 description 1
- 229920001543 Laminarin Polymers 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 241000195474 Sargassum Species 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 206010051373 Wound haemorrhage Diseases 0.000 description 1
- 201000004484 acute conjunctivitis Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001037 epileptic effect Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 108010030696 low density lipoprotein triglyceride Proteins 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 150000005830 nonesterified fatty acids Chemical class 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000008601 oleoresin Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229960003371 protocatechualdehyde Drugs 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000008802 xuezhikang Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/716—Clematis (leather flower)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/31—Extraction of the material involving untreated material, e.g. fruit juice or sap obtained from fresh plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种用于治疗高脂血症的胶囊及制备方法,属中药领域;本发明胶囊有效成分的原料组成为:荠菜、八月札、水芹、甘木通、大黄、莴苣子、荞麦、西红柿、昆布、半截叶、没药、火绒草、红花、番木瓜、山楂和夏天无;本发明胶囊是在传统中医辩证施治的基础上结合临床实践研制而成的,诸药相合具有疏肝和胃、软坚散结、清热解毒、活血行瘀、健脾消积、降压止痛等功效,对于治疗高脂血症引起的发热头晕、神疲乏力、失眠健忘、肢体麻木、胸闷、心悸等症状具有见效快、治愈率高、无毒副作用、安全方便的优点,可广泛应用于高脂血症的临床治疗。
Description
所属技术领域
本发明涉及中药领域,尤其涉及一种用于治疗高脂血症的胶囊及制备方法。
背景技术
高脂血症是指血脂水平过高,可直接引起一些严重危害人体健康的疾病,如动脉粥样硬化、冠心病、胰腺炎等。
高脂血症的临床表现主要是脂质在真皮内沉积所引起的黄色瘤和脂质在血管内皮沉积所引起的动脉硬化。尽管高脂血症可引起黄色瘤,但其发生率并不很高;而动脉粥样硬化的发生和发展又是一种缓慢渐进的过程。因此在通常情况下,多数患者并无明显症状和异常体征。不少人是由于其他原因进行血液生化检验时才发现有血浆脂蛋白水平升高。
大量研究资料表明,高脂血症是脑卒中、冠心病、心肌梗死、猝死的危险因素。此外,高脂血症也是促进高血压、糖耐量异常、糖尿病的一个重要危险因素。高脂血症还可导致脂肪肝、肝硬化、胆石症、胰腺炎、眼底出血、失明、周围血管疾病、跛行、高尿酸血症。所以必须高度重视高脂血症的危害,积极的预防和调理。
目前治疗高脂血症的中、西医药物有很多,虽有一定的疗效,但效果不佳,不能达标本兼治的目的,且费用较高,给患者带来较大的心理负担和经济负担。为此,我们急需研制一种安全无副作用的中药来帮助患者摆脱高脂血症带来的痛苦。
发明内容
本发明提供了一种用于治疗高脂血症的胶囊及制备方法;本发明胶囊是在传统中医辩证施治的基础上结合临床实践研制而成的,诸药相合具有疏肝和胃、软坚散结、清热解毒、活血行瘀、健脾消积、降压止痛等功效,对于治疗高脂血症引起的发热头晕、神疲乏力、失眠健忘、肢体麻木、胸闷、心悸等症状具有见效快、治愈率高、无毒副作用、安全方便的优点,可广泛应用于高脂血症的临床治疗。
为实现上述目的,本发明的技术方案实施如下:
一种用于治疗高脂血症的胶囊,制成所述胶囊有效成分的原料组成及重量份数为:
制成所述胶囊有效成分的原料组成及重量份数为:
制成所述胶囊有效成分的原料组成及重量份数为:
制成所述胶囊有效成分的原料组成及重量份数为:
一种用于治疗高脂血症的胶囊的制备方法,包括以下工艺步骤:
(1)将荠菜、甘木通、莴苣子、荞麦、西红柿、昆布、火绒草、红花、番木瓜、山楂和夏天无放入容器中,首先加入10-15倍量蒸馏水浸泡4-5小时后,加热煮沸3-4小时,提取;第二次加8-10倍量蒸馏水加热煮沸2-3小时,提取;第三次加6-8倍量蒸馏水加热煮沸1-2小时,提取;合并提取液,滤过,得滤液备用;
(2)将八月札、大黄和半截叶加10倍量体积浓度70%乙醇提取三次,每次3小时,滤过,合并滤液,放置过夜,回收乙醇并浓缩至60℃相对密度为1.12-1.151的浓液备用;
(3)将水芹捣汁,滤杂质,留汁液,备用;
(4)将拣净的没药置锅内用文火炒至表面稍见熔化时,喷洒米醋,继续炒至外层明亮光透,取出放凉,研末,得到过180目的细粉,备用;
(5)将步骤(1)-步骤(4)制得的滤液、浓液、汁液和细粉混合,制成胶囊,即为所述的用于治疗高脂血症的胶囊。
本发明所用中药的药性如下:
荠菜:味甘、淡,性凉;归肝、心、肺经。凉肝止血,平肝明目,清热利湿。主叶血,衄血,咯血,尿血,崩漏,目赤疼痛,眼底出血,高血压病,赤白痢疾,肾炎水肿,乳糜尿。《广西中药志》载:“健胃消食,化积滞。”
八月札:味微苦,性平;归肝、胃、膀胱经。疏肝和胃,活血止痛,软坚散结,利小便。主肝胃气滞,脘腹、胁助胀痛,饮食不消,下痢便泄,疝气疼痛,腰痛,经闭痛经,瘿瘤瘰疬,恶性肿瘤。《陕西中草药》载:“疏肝益肾,健脾和胃。治消化不良,腹痛,泻痢,疝气,子宫下坠。”
水芹:味辛、甘,性凉;归肺、肝、膀胱经。清热解毒,利尿,止血。主感冒,暴热烦渴,吐泻,浮肿,小便不利,淋痛,尿血,便血,吐血,衄血,崩漏,经多,目赤,咽痛,喉肿,口疮,牙疳,乳痈,痈疸,瘰疬,痄腮,带状疱疹,痔疮,跌打伤肿。《医林纂要》载:“补心,去瘀,续伤。”实验表明,水芹有降低β脂蛋白、三酰甘油(甘油三酯)作用。
甘木通:味苦,性微凉;归心、肝经。清肝火,宁心神,降血压,通络止痛。主高血压病,失眠,头痛,四肢麻木,肝经风热,目赤肿痛,风火牙痛,风湿痹痛。实验证明,25%甘木通叶煎剂对离体兔心冠脉流量平均增加39%。
大黄:味苦,性寒。泻实热,破积滞,行瘀血。主实热便秘,食积停滞,腹痛,急性阑尾炎,急性传染性肝炎,血瘀经闭,牙痛,衄血,急性结膜炎;外用治烧烫伤,化脓性皮肤病,痈肿疮疡。《本经》载:“下瘀血,血闭,寒热,破症瘕积聚,留饮宿食,荡涤肠胃,推陈致新,通利水谷,调中化食,安和五脏。”现代医学研究证实,本品有降低血清高胆固醇的作用。
莴苣子:味辛、苦,性微温;归胃、肝经。通乳汁,利小便,活血行瘀。主乳汁不通,小便不利,跌打损伤,瘀肿疼痛,阴囊肿痛。现代医学研究证实,莴苣子总黄酮对心律失常有显著拮抗作用。
荞麦:味甘、微酸,性寒;归脾、胃、大肠经。健脾消积,下气宽肠,解毒敛疮。主肠胃积滞,泄泻,痢疾,绞肠癌,白沙,带下,自汗,盗汗,疱疹,丹毒,痈疽,发背,瘰病,烫火伤。《纲目》载:“降气宽肠,磨积滞,消热肿风痛,除白浊白带,脾积泄泻。”现代医学研究证实,本品使极低密度脂蛋白-胆固醇、极低密度脂蛋白-三酸甘油、低密度脂蛋白-三酰甘油和高密度脂蛋白-三酰甘油明显降低。
西红柿:味酸、甘,性微寒。生津止渴,健胃消食。主口渴,食欲不振。现代医学研究证实,西红柿具有降脂降压作用。
昆布:味咸,性寒;归肝、胃、肾、脾经。消痰软坚,利水退肿。主瘰疬,瘿瘤,噎膈,(疒颓)疝脚气水肿。《玉楸药解》载:“泄水去湿,破积软坚。清热利水,治气臌水胀,瘰疬瘿瘤,TUI疝恶疮,与海藻、海带同功。”现代医学研究证实,海带多糖同时具有降血脂和抗凝作用。
半截叶:味微苦,性温。祛风湿,补肝肾,活血调经,杀虫截疟。主风温滑痛,腰酸背痛,肝炎,肝硬化,月经不调,跌打损伤,骨折,疟疾,蛔虫病。《云南思茅中草药选》载:“舒筋活络,散瘀活血,止咳化痰,驱虫。治风湿骨痛,关节炎,疟疾,痰阻,蛔虫症。”
没药:味苦,性平;归肝、脾、心、肾经。活血止痛,消肿生肌。主胸腹瘀痛,痛经,经闭,症瘕,跌打损伤,痈肿疮疡,肠痈,目赤肿痛。《药性论》载:“主打扑损,心腹血瘀,伤折跌损,筋骨瘀痛,金刃所损,痛不可忍,皆以酒投饮之。”现代医学研究证实,没药肿含油树脂部分能降低雄兔高胆甾醇血症(饲氢化植物油造成)的血胆甾醇含量,并能防止斑块形成,也能使家兔体重有所减轻。
火绒草:味微苦,性寒。疏风清热,利尿,止血。主流行性感冒,急、慢性肾炎,尿路感染,尿血,创伤出血。现代医学研究证实,火绒草乙醇提取物分离出原儿茶醛,该成分为治疗肾炎的主要有效成分之一,并具有增加冠脉血流量的作用。
红花:味辛,性温;归心、肚经。活血能经,祛瘀止痛。主经闭,痛经,产后瘀阻腹痛,胞痹心痛症瘕积聚,跌打损伤,关节疼痛,中风偏竣,斑疹。《本草衍义补遗》载:“红花,破留血,养血。多用则破血,少用则养血。”现代医学研究证实,本品可降低血清中总胆甾醇、总脂、三硝酸甘油酯吸非酯化脂肪酸的水平。
番木瓜:味甘,性平。消食下乳,除湿通络,解毒驱虫。主消化不良,胃、十二指肠溃疡疼痛,乳汁稀少,风湿痹痛,肢体麻木,湿疹,烂疮,肠道寄生虫病。姚可成《食物本草》载:“主利气,散滞血,疗心痛,解热郁。”
山楂:味酸、甘,性微温;归脾、胃、肝、肺经。消食积,散瘀血,驱绦虫。治肉积,症瘕,痰饮,痞满,吞酸,泻痢,肠风,腰痛,疝气产后儿枕痛,恶露不尽,小儿乳食停滞。消食健胃,行气散瘀。用于肉食积滞、胃烷胀满、泻痢腹痛、瘀血经闭、产后瘀阻、心腹刺痛、疝气疼痛、高血脂症。宁原《食鉴本草》载:“化血块,气块,活血。”现代医学研究证实,山植提取物和醇浸膏0.5mg/kg口服能使动脉粥样硬化兔血中卵磷脂比例提高,胆固醇和脂质在器官上的沉积降低。
夏天无:味苦、辛,性凉;归肝、肾经。祛风除湿,舒筋活血,通络止痛,降血压。主风湿性关节炎,中风偏瘫,坐骨神经痛,小儿麻痹后遗症,腰肌劳损,跌扑损伤,高血压。江西《中草药学》载:“降压止痛,行气活血。治各型高血压、偏瘫症,风湿性关节炎,腰肌劳损。”现代医学研究证实,夏天无生物碱溶液具有延长小白鼠血凝时间;增加犬冠状动脉血流量和降压作用。
本发明与现有技术相比,具有以下有益效果:
本发明胶囊是在传统中医辩证施治的基础上结合临床实践研制而成的,诸药相合具有疏肝和胃、软坚散结、清热解毒、活血行瘀、健脾消积、降压止痛等功效,对于治疗高脂血症引起的发热头晕、神疲乏力、失眠健忘、肢体麻木、胸闷、心悸等症状具有见效快、治愈率高、无毒副作用、安全方便的优点,可广泛应用于高脂血症的临床治疗。
具体实施方式
下面结合具体实施例对本发明做进一步阐述。
实施例1
本发明胶囊有效成分的原料组成及重量为:
本发明胶囊制备方法的工艺步骤为:
(1)将荠菜、甘木通、莴苣子、荞麦、西红柿、昆布、火绒草、红花、番木瓜、山楂和夏天无放入容器中,首先加入10-15倍量蒸馏水浸泡4-5小时后,加热煮沸3-4小时,提取;第二次加8-10倍量蒸馏水加热煮沸2-3小时,提取;第三次加6-8倍量蒸馏水加热煮沸1-2小时,提取;合并提取液,滤过,得滤液备用;
(2)将八月札、大黄和半截叶加10倍量体积浓度70%乙醇提取三次,每次3小时,滤过,合并滤液,放置过夜,回收乙醇并浓缩至60℃相对密度为1.12-1.151的浓液备用;
(3)将水芹捣汁,滤杂质,留汁液,备用;
(4)将拣净的没药置锅内用文火炒至表面稍见熔化时,喷洒米醋,继续炒至外层明亮光透,取出放凉,研末,得到过180目的细粉,备用;
(5)将步骤(1)-步骤(4)制得的滤液、浓液、汁液和细粉混合,制成胶囊,即为所述的用于治疗高脂血症的胶囊。
用法用量:口服,每日2次,每次2粒,10天为一疗程,轻者2到5个疗程即可痊愈,病情严重者遵医嘱酌增用量。
实施例2
本发明胶囊有效成分的原料组成及重量为:
本实施例的胶囊制备方法工艺步骤及用法用量与实施例1相同。
实施例3
本发明胶囊有效成分的原料组成及重量为:
本实施例的胶囊制备方法工艺步骤及用法用量与实施例1相同。
实施例4
本发明胶囊有效成分的原料组成及重量数为:
本实施例的胶囊制备方法工艺步骤及用法用量与实施例1相同。
临床资料:
病例选择:
作为治疗高脂血症的胶囊,选择我院或外院确诊的高脂血症患者176例临床观察,病人随机分成两组,治疗组88例,其中男性44例,女性44例,年龄20-70岁,平均年龄42.9岁,病程1年-17年;对照组88例,其中男性44例,女性44例,年龄30-76岁,平均年龄39.5岁,病程1年-13年。两组病例的病程、症状轻重程度基本一致,无显著差异,具有可比性。
2、药物选择:
治疗组患者服用本发明胶囊,成人每日2次,每次2粒,饭后半小时内温开水送服,10天为一疗程,连续服用2到5个疗程即可痊愈,病情严重者遵医嘱酌增用量。
对照组服用辛伐他汀,按说明书用,病情严重者遵医嘱酌增用量。
3、疗效判定:
(1)治愈:头晕、神疲乏力、失眠健忘、肢体麻木、胸闷、心悸等症状消失,身体恢复正常。
(2)有效:上述症状有所缓解。
(3)无效:病症无变化。
4、结果:
服用本发明胶囊的治疗组中,治愈60例,有效25例,无效3例,治愈率为68.2%,总有效率96.6%。
对照组中治愈23例,有效25例,无效40例,治愈率为26.1%,总有效率54.5%。
以上结果显示,治疗组治愈率和总有效率明显高于对照组。
典型病例举例:
1、葛某,男,62岁,退休干部,陕西安康人。患者有高脂血症病史10年,经常出现头晕、神疲乏力、肢体麻木、胸闷、心悸等症状。间断服用辛伐他丁、非诺贝特、血脂康等药物,血脂始终降不下来。为求进一步诊治来我院就诊。给予服用本发明胶囊2个疗程后,上述症状好转,继续服用本发明胶囊3个疗程,身体痊愈,随访未复发。
2、高某,男,50岁,企业管理者,江苏常州人。患者吸烟史20余年,已戒烟4年,且高脂血症病史4年,规律服用阿托伐他汀,每日20mg,后因间断胸痛胸闷、心悸等症状加重来我院就诊。给予服用本发明胶囊1个疗程后,上述症状好转,继续服用本发明胶囊3个疗程后,上述症状消失,随访未复发。
3、向某,男,45岁,经理,江西南昌人。患者6年前在例行体检时发现血压升高,最高达170/110mmHg,无头晕、头痛及心悸,一直规则服用氨氯地平及美托洛尔治疗,血压控制在130/80mmHg左右。1年前在我院检查发现血脂增高。给予服用本发明胶囊2个疗程后,血脂下降,继续服用本发明胶囊2个疗程后,血脂恢复正常,身体痊愈,随访未复发。
4、万某,女,36岁,银行职员,山西运城人。患者2年前无明显诱因出现头晕,并伴有左侧肢体持续性麻木,下肢为重。来我院就诊,经检查确诊为高脂血症。给予服用本发明胶囊2个疗程,上述症状减轻。继续服用本发明胶囊2个疗程,上述症状全部消失,随访未复发,彻底治愈。
5、刘某,男,24岁,销售,河南洛阳人。患者无明显诱因出现头晕,并伴有右侧肢体持续性麻木,下肢为重。在当地医院给予药物治疗后,未有明显好转。后来我院就诊,确诊为高脂血症。给予服用本发明胶囊2个疗程后,上述症状好转,继续服用本发明胶囊3个疗程,身体痊愈,随访未复发。
6、梁某,女,22岁,学生,浙江绍兴人。患者无明显诱因出现头晕、神疲乏力、失眠健忘、肢体麻木、胸闷等症状。在当地医院确诊为高脂血症,给予药物治疗后未有好转,为求进一步诊治来院就诊。给予服用本发明胶囊2个疗程后,上述症状好转。服用2个疗程后,上述症状消失,身体痊愈,随访未复发,彻底治愈。
Claims (5)
1.一种用于治疗高脂血症的胶囊,其特征在于:制成所述胶囊有效成分的原料组成及重量份数为:
荠菜66-86份八月札54-74份水芹54-74份甘木通51-71份
大黄51-71份莴苣子44-64份荞麦44-64份西红柿36-56份
昆布36-56份半截叶31-51份没药31-51份火绒草21-41份
红花16-36份番木瓜16-36份山楂11-31份夏天无9-21份。
2.根据权利要求1所述的一种用于治疗高脂血症的胶囊,其特征在于:制成所述胶囊有效成分的原料组成及重量份数为:
荠菜81份八月札69份水芹69份甘木通66份
大黄66份莴苣子59份荞麦59份西红柿51份
昆布51份半截叶46份没药46份火绒草36份
红花31份番木瓜31份山楂26份夏天无18份。
3.根据权利要求1所述的一种用于治疗高脂血症的胶囊,其特征在于:制成所述胶囊有效成分的原料组成及重量份数为:
荠菜76份八月札64份水芹64份甘木通61份
大黄61份莴苣子54份荞麦54份西红柿46份
昆布46份半截叶41份没药41份火绒草31份
红花26份番木瓜26份山楂21份夏天无15份。
4.根据权利要求1所述的一种用于治疗高脂血症的胶囊,其特征在于:制成所述胶囊有效成分的原料组成及重量份数为:
荠菜71份八月札59份水芹59份甘木通56份
大黄56份莴苣子49份荞麦49份西红柿41份
昆布41份半截叶36份没药36份火绒草26份
红花21份番木瓜21份山楂16份夏天无12份。
5.一种如权利要求1-4任一项所述的用于治疗高脂血症的胶囊的制备方法,其特征在于:包括以下工艺步骤:
(1)将荠菜、甘木通、莴苣子、荞麦、西红柿、昆布、火绒草、红花、番木瓜、山楂和夏天无放入容器中,首先加入10-15倍量蒸馏水浸泡4-5小时后,加热煮沸3-4小时,提取;第二次加8-10倍量蒸馏水加热煮沸2-3小时,提取;第三次加6-8倍量蒸馏水加热煮沸1-2小时,提取;合并提取液,滤过,得滤液备用;
(2)将八月札、大黄和半截叶加10倍量体积浓度70%乙醇提取三次,每次3小时,滤过,合并滤液,放置过夜,回收乙醇并浓缩至60℃相对密度为1.12-1.151的浓液备用;
(3)将水芹捣汁,滤杂质,留汁液,备用;
(4)将拣净的没药置锅内用文火炒至表面稍见熔化时,喷洒米醋,继续炒至外层明亮光透,取出放凉,研末,得到过180目的细粉,备用;
(5)将步骤(1)-步骤(4)制得的滤液、浓液、汁液和细粉混合,制成胶囊,即为所述的用于治疗高脂血症的胶囊。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610032104.XA CN105477171A (zh) | 2016-01-18 | 2016-01-18 | 一种用于治疗高脂血症的胶囊及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610032104.XA CN105477171A (zh) | 2016-01-18 | 2016-01-18 | 一种用于治疗高脂血症的胶囊及制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105477171A true CN105477171A (zh) | 2016-04-13 |
Family
ID=55664685
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610032104.XA Pending CN105477171A (zh) | 2016-01-18 | 2016-01-18 | 一种用于治疗高脂血症的胶囊及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105477171A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106109946A (zh) * | 2016-08-22 | 2016-11-16 | 肖�琳 | 一种治疗继发性高脂血症的生物胶囊及制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103893327A (zh) * | 2014-04-19 | 2014-07-02 | 姜彩霞 | 一种治疗高脂血症的中药制剂及制备方法 |
-
2016
- 2016-01-18 CN CN201610032104.XA patent/CN105477171A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103893327A (zh) * | 2014-04-19 | 2014-07-02 | 姜彩霞 | 一种治疗高脂血症的中药制剂及制备方法 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106109946A (zh) * | 2016-08-22 | 2016-11-16 | 肖�琳 | 一种治疗继发性高脂血症的生物胶囊及制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104383132B (zh) | 一种用于治疗胃溃疡的中药制剂及制备方法 | |
CN104147552A (zh) | 一种治疗血瘀型产后腹痛的中药组合物及其制备方法 | |
CN103211930A (zh) | 一种降血脂、降血压的中药制剂 | |
CN103623280B (zh) | 一种治疗心脑血管疾病的中药制剂 | |
CN104398980A (zh) | 一种治疗中风后偏瘫的中药制剂及其制备方法 | |
CN104815037A (zh) | 一种治疗风湿蕴毒型慢性湿疹的药物及其制备方法 | |
CN109820943B (zh) | 一种治疗痛风的壮药制剂及其制备方法 | |
CN101607067B (zh) | 一种治疗胆结石的中药制剂及制备方法 | |
CN104857210A (zh) | 一种治疗脂肪肝的中药组合制剂及其制备方法 | |
CN104043058A (zh) | 一种治疗肾虚型腰椎间盘突出的中药制剂及其制备方法 | |
CN103860773A (zh) | 用于治疗心肌缺血的中药组合物及其制备方法 | |
CN105477171A (zh) | 一种用于治疗高脂血症的胶囊及制备方法 | |
CN102266435A (zh) | 一种专治牛皮癣的中药 | |
CN104338052A (zh) | 治疗脑血栓的中药配方 | |
CN104758701A (zh) | 一种胃结石碎石后护理治疗的药物及其制备方法 | |
CN104873602A (zh) | 一种治疗乳腺增生的中药 | |
CN104689240A (zh) | 一种治疗气滞血瘀型黄褐斑的药物及其制备方法 | |
CN103933402A (zh) | 一种治疗脑瘤的中药制剂及制备方法 | |
CN103721028B (zh) | 一种治疗心绞痛的药物及制备方法 | |
CN103520644B (zh) | 用于治疗痰瘀型高脂血症的中药组合物及其制备方法 | |
CN105709005A (zh) | 一种乳康丸 | |
CN105031335A (zh) | 一种胃结石微波碎石后护理治疗的药物及其制备方法 | |
CN104127620A (zh) | 一种治疗股骨头坏死的中药制剂 | |
CN103638188A (zh) | 一种用于防治慢性骨髓炎的中药及其制备方法 | |
CN103893496A (zh) | 一种治疗心绞痛的中药制剂及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160413 |